In 2009
Release time: 2010-01-08 & nbsp & nbsp & nbsp Source:
| Market competition in the pharmaceutical industry is like a boat in the water，Back if you do not enter。After experiencing the pain of growth，They may have formed a certain scale，Or has a unique highlight，or has entered a benign development trajectory，or has a clear strategic prospect，or already has a certain brand awareness and reputation ... but there is no doubt，They are all growing，It is moving forward quickly with a strong momentum。
Qilu Pharmaceutical: Export globalization
September 2009，Qilu Pharmaceutical was by the Shandong Provincial Department of Commerce、Shandong Provincial Department of Science and Technology jointly approved "Shandong Province Science and Technology Export Innovation Base"，By optimizing export products and structures，Improve independent innovation ability，Enhance international competitiveness。
While establishing a solid drug research and production capacity，Qilu has also built a strict and standardized quality control agency and a perfect quality assurance system，Lay the foundation for the exit。Qilu is the first batch of State Food and Drug Administration GMP certification enterprises，Among them, non -sterile ingredients (fermentation、Chemical synthesis)、Steriles and drugs and various preparations have also passed the US Food and Drug Administration (USFDA)、European Drug Quality Council (EDQM)、British MHRA、The South African Medical Management Committee (MCC) and the certification of drug supervision agencies in other countries。Enterprise actively expand international market，Products are exported to Europe、North America、South America and Southeast Asia。
Kyushu Tong: Circle Movement
Under the background of the new medical reform，Major pharmaceutical business enterprises have begun to move in circles。December 18, 2009，Kyushu Tong announced that it spent 300 million yuan in Shanghai to build the largest modern pharmaceutical logistics center in Asia。The logistics center is expected to be completed and put into operation in 2011，After completion, you can store more than 30,000 quality rules、600,000 boxes of medicines，Can support annual sales of 10 billion yuan，will be Asia's largest、The most advanced modern pharmaceutical logistics center in China。
Kyushu Tong's long -established listing plan，There is also a more clear timetable，It is expected to be listed in A shares in 2010，At present, all preparations are also advancing steadily，The newly constructed pharmaceutical logistics center project in Shanghai is a big hand invested before the listing of Kyushu.。
stake online sports bettingIn stake online sports bettingaddition to the establishment of a modern pharmaceutical logistics center in East China，Next year Kyushu will still be in Nanning、Harbin、Hefei and other places Establish a large modern pharmaceutical logistics center。
As of now，Kyushu Tong has planned and constructed 34 pharmaceutical logistics distribution centers nationwide，and have large modern pharmaceutical logistics distribution centers in 14 provincial cities。
2008，Kyushu Tong has stabilized the third place in the national pharmaceutical business enterprise with a sales of 18.9 billion yuan，It is estimated that sales in 2009 will reach 22 billion yuan。
At present, Kyushu Tong has also begun to seek transformation，I hope to cut into the mainstream pharmaceutical market that accounts for 80%of the Chinese pharmaceutical consumer market。
Ruiyang: The scale is excellent
September 2009，Ruiyang's newly -built annual output of 400 million cephalosphamic pink pink pink needle preparation workshops successfully passed the national GMP certification inspection，With the country's largest bicycle pink needle and frozen dried powder needle production line，Powder needle packaging scale ranks in the top five in the country。
Currently Ruiyang has raw materials、Pink needle、Frozen dried powder injections、tablets、Capsules、Granules、Small capacity injection、Oral liquid、Ambolidation、More than 350 varieties such as the ten dosage types such as the co -agent，Annual output pink needle (frozen dried) doses of more than 2 billion bottles、Small capacity injection of 200 million pieces、Tablets more than 2 billion tablets、Capsules of 1 billion capsules、Granular doses of more than 100 million bags、More than 10 million pieces of suppositories、APIP1,600 tons or more。It has the production capacity of 1,000 tons of cephalosporin aseptic sterile，Become one of the country's largest cephalosporin ingredients production base，provides sufficient raw material supply and quality guarantee for the production of cephalosporin powder needle preparations。
Leading product Melacylin sodium ingredients and their preparations、Puerathin for injection、Gegen Decoction Granules、Watsongbang and other varieties of domestic market share all ranked first。New Medicine Mimerlin Sodium is successfully launched and launched，Sales revenue accounted for 80%of the company's total sales revenue in just 2 years。
Data display，Ruiyang Pharmaceutical ranks 28th in the sorting of all industrial enterprise legal person units in accordance with the main business income，The legal person unit of the chemical drug industry enterprise is ranked 19th in the sorting of the main business income。
2009，Ruiyang has 42 varieties that enter the basic drug directory，Ruiyang ranked 21st in the Chinese hospital in 2008，Hospital medication accounts for about 50%of the company's drug sales。
With the new medical insurance、In -depth implementation of the basic drug system，Ruiyang Pharmaceutical Production Number Number、Full types of medicines、The scale advantage of sufficient production capacity will be more prominent。
stake online sports betting
As a leading company as a hemorrhoid drug，Treatment of hemorrhoids has always been the main business profit source of Ma Yinglong，2006 to the first three quarters of 2009 this type of product profit accounted for 91%of the company's main business profit。In the first three quarters of 2009，Main varieties of Ma Yinglong hemorrhoid cream realizes sales revenue of 120 million stake betting appyuan，Stake Sports Bettingincreased by 30%year -on -year; Ma Yinglong hemorrhoid throlls achieved sales revenue of 100 million yuan，increased by 20%year -on -year。New Olympic Film Movies in 2008、Hemorrhoids, such as hemorrhoids, etc., further improved the product structure，The former sales revenue of 16 million yuan in the first three quarters of 2009，increased by 60%year -on -year; the latter sales of 10 million，increased by 40%year -on -year。
Ma Yinglong launched Babao Eye Cream in June 2009，Sales of 3 months of sales of about 10,000 pieces，The market has a higher degree of recognition of its efficacy，Product gross profit margin is as high as 90%，It is expected to become an important profit growth point for the company in the future。
In addition，Martonglon musk hemorrhoid cream and other exclusive Chinese medicine varieties enter the 2009 edition "National Basic Medical Insurance、Work Injury Insurance and Maternity Insurance Drug Catalog "，It will bring long -term benefits to Ma Yinglong。
Shuzhong Pharmaceutical: Enter the county hospital
Sales in 2008 were 1.2 billion yuan，Sales in 2009 are expected to achieve 1.8 billion yuan，Shuzhong has achieved benign、High -speed、Sustainable development。
Ten years of entrepreneurial period，Deeper into the third terminal，Become the Queen of Pharmaceutical，Shuzhong began to seek strategic transformation，While based on the grassroots market，Start involved in hospitals at or above the county level。At present, it has established a brand prescription department，Use conference marketing to directly hit the terminal of hospitals at or above the county level，At the same time as the establishment of a sales team in 25 provinces and cities across the country，Agent cooperation with major cities chain pharmacies nationwide。The company's cooperation with major cities chain pharmacies has entered a substantive stage。In addition，It is in Sichuan、Guizhou、Yunnan、Marketing work in Jiangxi and other places has also achieved staged progress。
On the product，Shuzhong also began to take the road of brand strategy。In 2009, we will make full effort to create antibacterial anti -inflammatory capsules、Three Seven Film、3 varieties of Xuan wheat particles，and plan，Through independent research and development、Powerful United Union、Buy external purchase、Combined combination and other methods，Development advantage varieties，Prepare for the main market for entering the hospital。
At present, Shuzhong has completed the marketing trend of comprehensive coverage of the terminal market，and form the backing of the grass -roots market，Strategic deployment of gradually penetrating the high -end market as the starting point。
Zheng Da Tianqing: R & D of force
At present, Jiangsu Zhengda Tianqing started strategic transformation，Heavy Gold Cultivation R & D field。In 2009, the company invested about 100 million yuan in R & D funds，More than 30 development projects for the whole year，Number of the number of the number of years，Among them, the establishment of innovative drugs is significantly increased。
The company's licorice and technology transformation、The company's licorice and technology transformation、Heinonutang raw materials and their preparations have officially entered the "National Eleventh Five -Year Popular New Medicine Creation" project funding plan，The company's research and development capabilities and levels in innovative drugs have entered the advanced ranks of the same industry in China。
As of October 2009，Company stake betting apppatent My stake betting appapplication reaches 127 items，Invention patent application reaches 106 items，Among them, 57 items authorized patent，Invention patents 37 items。
Imitation is the development of R & D that is strongly advocated by Zhengda Tianqing。In 2009 and the next few years，The theme of its innovation will be mainly concentrated in liver disease、Tumor、Diabetes、Cardiovascular、Breathing and other key areas。
Yuekang: Expansion of production and market
December 12, 2009，Yuekang Pharmaceutical Group Shanghai Pharmaceutical Co., Ltd. laid the foundation in Jinshan Industrial Zone。About 100 acres of land for the project，Total investment of 350 million yuan，The first phase of the project will be completed in May 2010，officially put into production in June 2010，It is estimated that the annual sales after production can reach 1 billion yuan。
Yuekang Pharmaceutical is now in Anhui、Henan、Beijing、Wuhan and other places have built production bases，but only sales companies in Shanghai。Building Shanghai production base is an important part of Yuekang Pharmaceutical's strategic plan，Shanghai Construction Factory forms a great convenience in the management of Yuekang Pharmaceutical Supply Chain Management，It has also filled the strategic blank。
October 2009，Yuekang established Beijing Yuekang Logistics Co., Ltd.，Buy 300 professional drug transport containers，GPS positioning and temperature control system，Through international advanced logistics management system，Logistics facilities that meet the quality requirements of drugs，Management system for scientific norms，Make sure the qualified drugs that are leaving the factory are safe and fast to the patient's hands，It provides professionalization for the docking of Beijing pharmaceutical manufacturers and commercial companies with commercial companies、High -standard drug logistics service。
All Wentao Pharmaceuticals: Listing Dream Yuan
December 11, 2009，Guangdong Zhongsheng Pharmaceutical Co., Ltd. is listed on Mengyuan。
All Living Pharmaceuticals is a collection of drug research and development、High -tech enterprises integrating production and sales，Since its establishment in 2001，Growth quickly。
The company currently has 18 dosage forms，295 national medicine quasi -font -name drug varieties，Based on chemical drugs、Product structure dominated by Chinese patent medicine，In cardiovascular and cerebrovascular、Eye Disease、Salva disease、Clearing heat and other fields is particularly prominent。The leading product is compound thrombosis capsule、Tongxiang Pills and clearing heat and dampness granules。
2008，Compound thrombosis Capsule sales in the 16th digit of domestic cerebral blood vessels in China、The first place for domestic eye disease medicine、The first place in the market of cardiovascular and cerebrovascular in the market of Guangdong Hospital; the eighth position of the sales of Zhongsheng Pills in China、The first place in throat disease medicine in the retail market in Guangdong Province; the sales of heat -clearing and dehumidifying granules in China、The seventh place of the Chinese patent medicine category in Guangdong Province。
With the help of listing of funds raised by listing，All Living Pharmaceuticals will further improve product technology，Optimized product structure，Expand production and operation scale，Improve market competitiveness，Achievement continues、Quick、Healthy Development。
stake sports betting appstake online sports bettingGuizhou Magic: Love ethnic medicine
The main product of Guizhou's magic is a magical cough series、Wonderful Doll Series and Coral Tinea Clean，The total value of assets is as high as 3.2 billion yuan，Get 132 national invention patents，37 items of other patents，More than 130 registered trademarks，13 national medicines with independent intellectual property rights，38 exclusive varieties。
The company has become a national research base for Miao and Medicine，The "Guizhou Miao Medicine Preparation Engineering Technology Center" was established in its technology industrial park，Main seedlings include creamy cream、Yinzhan Heart Pill Pill、Jieyin Spirit Washing agent、Toothache Ning Di Pill、Fufang injury Funing cream、Six flavors injury Funing。
Sales teams for grass -roots health medical institutions this year，The magic of multiple exclusive varieties will get greater benefits。
Hainan Kangzhi: Focus on children's medicine
Hainan Kangzhi Pharmaceuticals has developed rapidly in recent years，The capacity of production scale with an annual output value of over 500 million yuan has been formed and the ability of an annual profit of 90 million yuan，and have the conditions for continuous development。2009，Kangzhi Pharmaceutical's sales growth will exceed 50%，higher than the industry average。
Kangzhi Pharmaceutical focuses on the development and production of children's medication，Investment in more than 10 million yuan a year conducts secondary research and development of the product，Taking professional pediatric medicine as the core variety，Change the pattern of domestic pediatric medicine with imported drugs and joint venture，formed its own domestic national brand。The fist product "Ruizhiqing", which has invested huge investment in the secondary R & D product "Ruizhiqing"，The share in market segments ranks first in China，Occupation of more than 60%of the country's market share。2009，"Ruizhiqing" sales still maintained a 50%high -speed growth。 |
